EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leveraging ZBP1 signaling for cancer immunotherapy

Parth Desai, Chunxia Wen, Siddharth Balachandran

Frontiers in Cell Death · 22.07.2026 · 5

DOI: 10.3389/fceld.2026.1841599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cell Death, online erschienen am 22.07.2026. Verfasst von Parth Desai und 2 weiteren Autor:innen. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed cancer care, yet durable responses remain limited in a majority of patients. This is particularly true of immunologically cold tumors, which are characterized by insufficient T-cell infiltration, low antigenicity, impaired adjuvanticity, and an immunosuppressive tumor microenvironment (TME). Z-form Nucleic Acid (Z-NA) Binding protein 1 (ZBP1)-initiated signaling, by overcoming these barriers, offers a mechanistic solution to rekindling ICI responsiveness in cold tumors. ZBP1 is an immune sensor which detects viral or endogenous Z-NAs, binds the kinase RIPK3, and activates Mixed Lineage Kinase Like pseudokinase (MLKL)-mediated necroptosis. ZBP1-initiated signaling can also inflame tumors non-cytolytically, including by activating inflammatory gene expression. Tumors frequently inactivate ZBP1 signaling, most notably by epigenetically silencing RIPK3. However, TME cells, particularly inflammatory cancer-associated fibroblasts (iCAFs), retain RIPK3 competence and represent a readily exploitable therapeutic vulnerability for activation of ZBP1-mediated immunogenic signaling within the tumor mass. Here, we discuss emerging strategies to activate ZBP1 within cold tumors as a means to enhance ICI-driven anti-tumor responses.

Zitieren

APA

Desai, P., Wen, C., & Balachandran, S. (2026). Leveraging ZBP1 signaling for cancer immunotherapy. Frontiers in Cell Death, 5. https://doi.org/10.3389/fceld.2026.1841599

Vancouver

Desai P, Wen C, Balachandran S. Leveraging ZBP1 signaling for cancer immunotherapy. Frontiers in Cell Death. 2026;5. doi:10.3389/fceld.2026.1841599

BibTeX
@article{Desai2026,
  author = {Desai, Parth and Wen, Chunxia and Balachandran, Siddharth},
  title = {Leveraging ZBP1 signaling for cancer immunotherapy},
  journal = {Frontiers in Cell Death},
  year = {2026},
  volume = {5},
  doi = {10.3389/fceld.2026.1841599}
}
Kostenlos starten →